Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
Eli Lilly said its sees growth from key treatments such as Trulicity, Taltz and Verzenio driving 2021 revenues to around $28 billion. Eli Lilly said 2020 revenues should come in between $24.2 ...
Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise ...
(Reuters) -Eli Lilly raised its annual revenue forecast by $2 billion on Tuesday due to strong demand and plans to increase production of its weight-loss treatment Zepbound and related diabetes drug ...
Eli Lilly shares were marked6.6% lower in early Thursday afternoon trading following the earnings release to change hands at $319.51 each, erasing all of the stock's six-month gains.
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly (NYSE:LLY)'s weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday ...
"Demand continues to outstrip even increased supply," Eli Lilly's CFO said of its Zepbound weight loss drug on the company's ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Soaring sales of Eli Lilly’s hugely popular diabetes and weight loss drugs Mounjaro and Zepbound prompted ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...